Skip to main content

Nasdaq

Markets Enter The Eye of the Coronavirus Storm

6 years 5 months ago
The past month has been pretty extraordinary. But there are signs that the market is starting to act more rationally and waiting on new data to see whether valuations are oversold, or need to be ratcheted down some more.
Phil Mackintosh

Where Will The Market Go From Here?

6 years 5 months ago
The coronavirus pandemic, which has caused a nationwide shutdown of the economy, forcing school closures and and bring business production to a screeching halt, is unprecedented. It’s unlike anything we’ve ever seen.
Richard Saintvilus

March 2020 Review and Outlook

6 years 5 months ago
Nasdaq’s Market Intelligence Desk (MID) is designed to provide critical touch-points for timely trading analysis and market information.
The Market Intelligence Desk Team

Finding A Reference Point for Assessing Value in Stocks

6 years 5 months ago
On Monday, I wrote that while stocks could be expected to hold onto most of the gains seen last week early in this week, the month’s, and therefore the quarter’s, end yesterday could prove to be a short-term turning point.
Martin Tillier

Is The Infrastructure Trade Back On?

6 years 5 months ago
Could one of President Trump’s early promises help the U.S. avoid a recession and get the economy (and stocks) moving back in the right direction?
Richard Saintvilus

Acting on Activism and Emerging Governance Trends

6 years 5 months ago
In a recent exclusive interview for our Nasdaq Amplify newsletter, Nasdaq's Karen Snow spoke with Betsy Atkins to discuss emerging governance trends in the boardroom including term limits, ESG and evolving activism behavior.
Nasdaq

Ownership Trends: Most Active Small Cap Funds

6 years 5 months ago
Nasdaq surveyed activity for five of the largest actively managed small-cap funds. We’ve recapped the activity and highlighted key trends and rotations to provide clarity on how these funds are being positioned in this Amplify exclusive.
Michael Spector

Should You Buy Pharma Stocks on Reports of A Cure or Vaccine?

6 years 5 months ago
Yesterday, stock in Johnson and Johnson (JNJ) surged eight percent after the company reported that it would begin clinical trials on humans for its Covid-19 vaccine, with an eye to it being available for general use early next year.
Martin Tillier
Checked
13 minutes 20 seconds ago
This feed is responsible for generating the rss feed related to the topic nasdaq original
Subscribe to Nasdaq feed